Phase III Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage III Pancreatic Adenocarcinoma (DIRECT)
The purpose of this phase III trial is to evaluate the safety and efficacy of NanoKnife IRE with or without modified FOLFIRINOX for stage III pancreatic cancer.
Study ID: 28-001-ONC
Trial Phase: Phase III
Trial Sponsor: Angiodynamics, Inc.
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, Irreversible Electroporation (IRE), FOLFIRINOX